Skip to main content
. Author manuscript; available in PMC: 2013 Sep 20.
Published in final edited form as: Sci Transl Med. 2013 Mar 20;5(177):177ra38. doi: 10.1126/scitranslmed.3005930

Figure 5. MSK-ALL04 relapsed B-ALL tumor cells retain CD19 expression and sensitivity to 19-28z T cell mediated killing.

Figure 5

A. CD19 and CD10 expression of B-ALL tumor cells from the initial diagnostic whole blood sample (left panel) and the post 19-28z relapsed sample. Displayed cells have been gated on CD45+7AAD− cells. B. Untransduced (UNT) T cells from the leukapheresis product or 19-28z T cells from the End-of-Product formulated cells were incubated with the post 19-28z relapsed B-ALL tumor cells. Effectors were incubated with tumor cells (radiolabeled with 51Cr) at a 36:1 E:T ratio for 4 hours. 51Cr release was measured and calculated as a killing efficiency as described (8).